A Phase 2 interventional study of Rituximab and Filgrastim in Lymphoma, AIDS-related and Lymphoma, Large B-Cell, Diffuse, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lymphoma, AIDS-Related with a site in United States — none open to participants now, 1 under way, none of them phase 3. Lymphoma, AIDS-Related · United States.
Among the 12 studies in Lymphoma, AIDS-Related with a site in United States, this one is the only one that started in 2001, is one of 5 in phase 2, and was the 7th registered.
25 studies on the registry are indexed under Lymphoma, AIDS-Related; 2 are open to participants now.
Browse Lymphoma, AIDS-Related studies →None of the 12 studies in Lymphoma, AIDS-Related with a site in United States is open now. The open studies under Lymphoma, AIDS-Related, anywhere →
Of the 2 Lymphoma, AIDS-Related studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6
First in 1997; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 18 across 13 interventional studies indexed under Lymphoma, AIDS-Related.
Median enrollment 17 across the 7 interventional studies, 290 across the 4 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 8 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
National Cancer Institute (NCI) has 5 studies filed under Lymphoma, AIDS-Related — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Lymphoma, AIDS-Related with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
Objectives:
Eligibility:
-Patients with non-Hodgkin's lymphoma and HIV infection 4 years of age and older who have not been treated previously with rituximab or cytotoxic chemotherapy.
Design:
Background:
This is a study to investigate in a preliminary fashion the feasibility of short course chemotherapy to participants with HIV-associated non-Hodgkin's lymphoma (HIV-NHL).
This study will investigate if the paradigm for treatment can be successfully changed from a standard of 6 cycles to one cycle beyond complete remission with 6 total allowable cycles.
Objective:
To assess with 90 percent probability that at least 50 percent of participants treated with short-course EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide and rituximab) will be progression free at one year.
Eligibility:
Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse large B cell lymphoma (DLBCL).
HIV+ serology.
All stages (I-IV) of disease.
Eastern Cooperative Oncology Group (ECOG) Performance status 0-4.
Non-Hodgkin's Lymphoma (NHL) previously untreated with cytotoxic chemotherapy.
Age greater than or equal to 18 years.
May not be pregnant or nursing.
May not have received previous rituximab.
Design:
Participants will be treated every three weeks with a combination of EPOCH and rituximab for one cycle beyond complete remission (CR)/complete response unconfirmed (CRu) by computed tomography (CT) scan of all detectable tumors for a minimum of three and maximum of six cycles. Following cycle 2, CT, positron emission tomography scans (PET), and bone marrow biopsies (if initially positive) will be performed.
At the conclusion of the study, we will estimate whether the number of cycles can be reduced using the paradigm. If the cumulative number of participants to relapse exceeds 25 percent by 6 months, the study will be closed.
Following the completion of chemotherapy, restaging will be performed 2 months following the end of treatment, then every 3 months for one year, every 6 months for one year, then every 12 months until relapse, death, or loss to follow up.
Antiretroviral therapy (ART) will be given concurrently with treatment regimen.
To study the effects of treatment approach on parameters of HIV disease, measurements of cluster of differentiation 4 (CD4) cells and viral loads will be made at baseline and at the completion of therapy, and then 2 months following the end of treatment, and then every 3-6 months for a total of 24 months following chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI). Note: Participants with aggressive B-cell lymphoma of the plasmablastic lymphoma sub-type who do not have surface CD20 expression, are also eligible.
(HIV) + serology.
All stages (I-IV) of disease.
(ECOG) Performance status 0-4
Non-Hodgkin's Lymphoma (NHL) previously untreated with cytotoxic chemotherapy; however, participants may be entered if they have had prior cyclophosphamide for an urgent problem at diagnosis (e.g., epidural cord compression, superior vena cava syndrome) and/or a single dose of intrathecal methotrexate (MTX) at the time of the pre-treatment diagnostic lumbar puncture
Age greater than or equal to 18 years
Laboratory tests (unless impairment due to respective organ involvement by tumor):
Ability of participant to provide .
EXCLUSION CRITERIA:
Previous rituximab
Pregnancy or nursing.
- Doxorubicin, etoposide, vincristine and cyclophosphamide are teratogenic and may be excreted in milk.
Current clinical heart failure or symptomatic ischemic heart disease.
Serious underlying medical condition or infection other than that would contraindicate subcutaneous (SC)-rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin (EPOCH-R).
Primary CNS lymphoma
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination chemo and biological therapy
Biological: Rituximab · Biological: Filgrastim · Drug: EPOCH
2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
Also known as: Rituxan
Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
Also known as: Neupogen
Drug page: Epoetin AlfaStudies of Epoetin AlfaEpoetin Alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
Also known as: etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride
Median Progression Free Survival (PFS)
PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed.
Time frame: The participants were followed for a median of 15.4 years.
Progression Free Survival at 1 Year
PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s).
Time frame: 1 year
Number of Participants With ≥ Grades 3-5 Non-hematologic Toxicity
Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: Date treatment consent signed to date off study, approximately 209 months and 17 days.
Median Overall Survival
Overall survival is time from treatment start date until date of death or date last known alive.
Time frame: The participants were followed for survival for a median of 15.4 years.
1 Year Overall Survival
Overall survival is time from treatment start date until date of death or date last known alive.
Time frame: 1 year
Median Duration of Complete Response/Complete Response Unconfirmed
Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.
Time frame: The participants were followed for duration of complete response or complete response unconfirmed for a median of 15.4 years.
Percentage of Participants With CR/CRu Lasting 1 Year
Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.
Time frame: 1 year
Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia
Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics.
Time frame: Date treatment consent signed to date off study, approximately 209 months and 17 days.
Number of Cycles of Hematologic Toxicity
Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).
Time frame: Up to 112 cycles (each cycle is 21 days + 7 days window)
Overall Response
Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month.
Time frame: The participants were followed for an average of 6 months to determine response to therapy.
Percentage of Participants With Complete Response
Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy).
Time frame: The participants were followed for an average of 6 months to determine response to therapy.
Median Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)
PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.
Time frame: Participants were followed for up to 10.2 years to determine their response on interim PET scans.
1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)
1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans. PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.
Time frame: 1 year
Recovery of CD4 T Cells (CD4) Counts
Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL.
Time frame: From the end of chemotherapy every 3 months for the first 2 years
Recovery of Human Immunodeficiency Virus (HIV) Viral Load
The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or \< 50 copies.
Time frame: Either following or concurrently with combination chemo and biological therapy, approximately every 6 to 8 weeks after therapy was completed up to 16 months
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Milestone | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Started | 68 |
| Completed | 65 |
| Not completed | 3 |
| Withdrew: Refused further treatment | 2 |
| Withdrew: Declined to participate (before treatment started) | 1 |
PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed.
| years | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Median Progression Free Survival (PFS) | 13.8 (10.2 to NA) |
PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s).
| percentage of participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Progression Free Survival at 1 Year | 79.1 (67.3 to 87.1) |
Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
| Participants | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|
| Serious infection | 17 | 0 | 0 |
| Neurologic event | 0 | 0 | 0 |
| Syncope | 1 | 0 | 0 |
| Confusion | 1 | 0 | 0 |
| Motor neuropathy | 0 | 1 | 0 |
| Vision disturbance | 1 | 0 | 0 |
| Hyperglycemia | 4 | 0 | 0 |
| Hypophosphatemia | 2 | 1 | 0 |
| Hypocalcemia | 2 | 0 | 0 |
| Hypokalemia | 1 | 1 | 0 |
| Hyponatremia | 1 | 0 | 0 |
| Dehydration | 1 | 0 | 0 |
| Mucositis/Stomatitis | 6 | 0 | 0 |
| Liver test abnormalities | 6 | 1 | 0 |
| Pancreatitis | 1 | 0 | 0 |
| Diarrhea | 2 | 0 | 0 |
| Constipation | 1 | 0 | 0 |
| Serious hemorrhage | 5 | 1 | 0 |
| Fatigue | 2 | 0 | 0 |
| Headache | 5 | 0 | 0 |
| Bone pain | 1 | 0 | 0 |
| Nausea | 0 | 1 | 0 |
| Anorexia | 0 | 1 | 0 |
| Hypoxia | 0 | 4 | 1 |
| Myelodysplastic syndrome | 0 | 0 | 1 |
Overall survival is time from treatment start date until date of death or date last known alive.
| years | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Median Overall Survival | 14.2 (13.2 to NA) |
Overall survival is time from treatment start date until date of death or date last known alive.
| percentage of participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| 1 Year Overall Survival | 83.7 (71.0 to 91.2) |
Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.
| years | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Median Duration of Complete Response/Complete Response Unconfirmed | 13.9 (13.1 to NA) |
Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy). Complete response unconfirmed (CRu) is when a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by \> 75% in sum of the products of the greatest diameters or are \< 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR.
| percentage of participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Percentage of Participants With CR/CRu Lasting 1 Year | 82.5 (70.7 to 89.9) |
Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics.
| Participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia | 18 |
Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0).
| cycles | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Febrile neutropenia | 25 |
| Neutropenia with a Nadir <500 cells/mm^3 | 112 |
| Neutropenia with a Nadir <100 cells/mm^3 | 77 |
| Thrombocytopenia with a Nadir <50,000 platelets/mm^3 | 40 |
| Thrombocytopenia with a Nadir <25,000 platelets/mm^3 | 6 |
| Anemia: hemoglobin <8 g/dL | 36 |
Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by \> 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month.
| Participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Complete Response | 53 |
| Complete Response Unconfirmed | 10 |
| Partial Response | 1 |
| Non-Responder - Stable Disease | 1 |
| Non-Responder - Progressive Disease | 1 |
Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm before therapy).
| percentage of participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Percentage of Participants With Complete Response | 95 |
PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.
| years | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Interim PET positive participants | 10.2 (0.4 to NA) |
| Interim PET negative participants | NA (NA to NA) |
1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans. PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.
| percentage of participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Interim PET scan positive 1-year PFS | 61.5 (30.8 to 81.8) |
| Interim PET scan negative 1 year PFS | 89.3 (70.4 to 96.3) |
Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL.
| months | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Recovery of CD4 T Cells (CD4) Counts | 2.5 (0 to 24) |
The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or \< 50 copies.
| months | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Recovery of Human Immunodeficiency Virus (HIV) Viral Load | 2 (0 to 16) |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
| Participants | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0) | 66 |
Collected over Date treatment consent signed to date off study, approximately 209 months and 17 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 12/67 (17.9%) | 23/67 (34.3%) | 66/67 (98.5%) |
| Event | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Febrile neutropeniaInfections and infestations | 6/67 |
| HeadacheNervous system disorders | 4/67 |
| CNS hemorrhage/bleedingNervous system disorders | 3/67 |
| Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)Infections and infestations | 3/67 |
| Infection without neutropeniaInfections and infestations | 3/67 |
| ConstipationGastrointestinal disorders | 2/67 |
| NauseaGastrointestinal disorders | 2/67 |
| PlateletsBlood and lymphatic system disorders | 2/67 |
| Secondary Malignancy-Other (Myelodysplasia/Leukemia) excludes metastasis from initial primaryNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/67 |
| Vision-blurred visionEye disorders | 2/67 |
| Event | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Neutrophils/granulocytes (ANC/AGC)Blood and lymphatic system disorders | 62/67 |
| Leukocytes (total WBC)Blood and lymphatic system disorders | 61/67 |
| HemoglobinBlood and lymphatic system disorders | 60/67 |
| LymphopeniaBlood and lymphatic system disorders | 58/67 |
| PlateletsBlood and lymphatic system disorders | 56/67 |
| Stomatitis/pharyngitis (oral/pharyngeal mucositis)Gastrointestinal disorders | 36/67 |
| NauseaGastrointestinal disorders | 33/67 |
| SGPT (ALT) (serum glutamic pyruvic transaminase)Hepatobiliary disorders | 33/67 |
| Fatigue (lethargy, malaise, asthenia)General disorders | 32/67 |
| Neuropathy-sensoryNervous system disorders | 31/67 |
| Age, Categorical(Participants) | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 66 |
| >=65 years | 0 |
| Age, Continuous(years) | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Mean | 42.36 ± 10.7 |
| Sex: Female, Male(Participants) | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Female | 11 |
| Male | 57 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 62 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 32 |
| White | 31 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(Participants) | Arm 1-Combination Chemo and Biological Therapy |
|---|---|
| United States | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. All large-scale genomic sequencing data will be shared with subscribers to database of Genotypes and Phenotypes (dbGaP).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol genomic data sharing (GDS) plan for as long as database is active.
Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Ran from Jan 2001 to primary completion in Nov 2020, 238 months.
Results were first posted in Jun 2022, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Epoetin Alfa
National Cancer Institute (NCI) →